Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, 20133, Italy
Location status: Recruiting
Location contact
Carla Carozzi, MD
CONTACT
+ 39 02 2394 ext. 2420
Carla Carozzi, MD
PRINCIPAL_INVESTIGATOR
Marco Gemma, MD
SUB_INVESTIGATOR
NCT Number: NCT06844838
To evaluate the effect of intraoperative sedation dosage on awakening and recovery of consciousness after elective neurosurgical surgery.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Milan, 20133, Italy
Location status: Recruiting
Carla Carozzi, MD
CONTACT
+ 39 02 2394 ext. 2420
Carla Carozzi, MD
PRINCIPAL_INVESTIGATOR
Marco Gemma, MD
SUB_INVESTIGATOR
The project will have a total duration of 24 months and will mainly consist of a data collection phase (months 1-24) and a data analysis and results publication phase (months 15-24). Preoperative clinical and socio-demographic data will be collected from patients' medical records. Psychological variables will be administered to the patient before elective neurosurgical surgery.
BIS-guided general anesthesia will be induced by administering sedative and analgesic drugs to the effector site Ce (Effect Site) by target-controlled infusion (TCI). Propofol and remifentanil will be titrated to maintain blood pressure, body temperature, pCO2 and SaO2 in a normal range and BIS values between 40 and 60. Pharmacological data will be relevant at the end of the intervention from the drug infusion pumps. The Recovery Room multidisciplinary team will assess the quality of awakening following the Awakening Chart (Figure 1). This assessment involves dichotomous scoring (yes/no; correct/incorrect) of specific items. To assess the recovery of consciousness, during the pre-extubation phase, simple requests/questions will be asked of the patient: show tongue; show two fingers; give phone number; state place; identify what day is today; report date of birth; notify residence; perform simple multiplication (e.g., 4x5). The following variables will be collected during the periestubation phase: cough, blood pressure ± 20% of baseline, chills, NRS > 3, RASS < -1 or > 0. An abbreviated version of the STAI questionnaire will also be administered to the patient to assess anxiety on awakening. Awakening is considered good and optimal only if a score of 13 is achieved.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
Correlation between intraoperative dosage of Propofol and Remifentanil with respect to dichotomous outcome related to quality of awakening post GA.
Time frame: 2 years
RASS (Richmond Assesmenet sedation scale) scale score at post-GA awakening Analysis of the association between perioperative indicators - age, BMI, Milan Complexity Score, APAIS - and outcome on awakening. The minimum RASS scale is - 5 (unresponsive patient after painfull stimulation) and the maximum is + 4 (comactive patient). The optimal RASS scale is 0/-1.
Time frame: 2 years
NRS (Numerical rating scale ) scale score at post-GA awakening Analysis of the association between perioperative indicators - age, BMI, Milan Complexity Score, APAIS - and outcome on awakening. The minimum NRS scale is 0 (no pain at all) and the maximum is 10 (the maximum pain ever suffered)
Contact information is provided by the study sponsor or research team.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Other
Acronym: FasTrack
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07403929
Chronic Pain, Fibromyalgia
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06791044
Atrophy, Bone Diseases
Nea Liosia, Athens, Greece
View Trial DetailsNCT07738718
Dental Anxiety, Neurologic Manifestations
Ar Rass, Al-Qassim Region, Saudi Arabia
View Trial DetailsNCT05563792
Agnosia, Chronic Pain
Indianapolis, Indiana, United States
View Trial Details